Please login to the form below

Opko

This page shows the latest Opko news and features for those working in and with pharma, biotech and healthcare.

Versartis crashes as VELOCITY trial veers off track

It’s not the first long-acting hGH to miss the mark in trials - earlier this year Pfizer and Opko’s once-weekly candidate also failed a phase III trial.

Latest news

Pfizer/Opko's long-acting growth hormone misses mark in trial

Pfizer/Opko's long-acting growth hormone misses mark in trial. Previously forecast as a blockbuster product, hGH-CTP fails to show significant change. ... Pfizer and partner Opko ended 2016 on a disappointing note after their long-acting drug for growth
Pfizer buys majority stake in Redvax

No financial details of the deal have been disclosed. This rounds off a busy M&A period for Pfizer which just a fortnight ago partnered with Opko Health on a late
RNA interference rebirth

TTR. TTR-mediated amyloidosis. I. TKM-ApoB. Tekmira. ApoB. hypercholesterolaemia. Stalled. bevasiranib. Opko Health.
Flicking the switch

Opko Health is developing bevasiranib for the treatment for wet age-related macular degeneration (AMD). ... In phase II trials, bevasiranib inhibited the growth of choroidal neovascularisation and Opko have now initiated a pivotal phase III trial that
Mastering the gene

Acuity plans to initiate its phase III programme in 2007 and in March the company agreed a merger with several partners to establish a publicly-traded company, Opko. ... If the trial goes as hoped, Opko may lead the race to reach the market with a siRNA

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Deal Watch May 2016

The manufacturing CRLs have been out in force and AstraZeneca is not the only company on the receiving end with OPKO receiving a CRL earlier in the year [March] in relation ... 293. OPKO Health/ Vifor Fresenius. Licence. Rayaldee in EP, CA, Mexico,
Pharma deals in June 2015

Opko's strategy in its $1.47bn acquisition of Bio-Reference Laboratories at $52.58 per share (approximately 60% premium) is to gain access to a range of diagnostic capabilities including ... Acquisition - company. 2, 050. Bio-Reference Laboratories/ OPKO
Pharma deals during December 2014

This product, named hGH-CTP, was in the portfolio of Prolor Biotech which Opko acquired in August 2013 for $480m. ... The upfront payment of $295m from Pfizer will go some of the way to recoup the price Opko paid for Prolor.
Deal Watch table for December 2014

Collaboration, licence. 581. Opko Health / Pfizer. Long-acting hGH-CTP for growth hormone deficiency in adults and children (p3).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

AstraZeneca appoints head of oncology

Prior to this, Dr Freedman served as GlaxoSmithKline's vice president of oncology R&D, and led OPKO Health's R&D department.
OPKO appoints vice president of medical affairs

OPKO appoints vice president of medical affairs. Dr Douglass Laidlaw brings experience from Relypsa and Sanofi. ... Miami-based OPKO Health has appointed Dr Douglass Laidlaw as vice president of medical affairs.

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Manager – Healthcare Advertising: Salary TBC

Account Director, Healthcare Advertising Agency: Salary TBC

Sudler London - Account Director: Competitive

Sudler London - Senior Medical Writer: Competitive

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Medical Writer - Creative and Scientific Projects: DOE

Healthcare PR Senior Account Manager: Salary TBC

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Account Manager- 4 days per week or full-time: Salary TBC

Systematic Review Lead- London: Negotiable

Market Access Consultant - Greater Manchester: Negotiable

Senior Medical Writer, MedComms Agency: Salary TBC

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Senior Medical Writer: Salary is DOE

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Writer, Healthcare Advertising, London: Excellent package

Associate Scientific Director: Salary TBC

Graduate Scientific Editor: DOE

Subscribe to our email news alerts

PMHub

Add my company

Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....